Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

new australia agricultural development company pty ltd - fipronil - bait - fipronil nitrile active 0.5 g/kg - household insecticide

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

innovate ag pty limited - clitoria ternatea extract - emulsifiable concentrate - clitoria ternatea extract extract active 400.0 g/l - mixed function pesticide

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

the hunter river company pty limited - fluazuron; 1-octyl-2-pyrrolidinone; 1-dodecyl-2-pyrrolidinone; 1-methyl-2-pyrrolidinone - topical solution/suspension - fluazuron ungrouped active 25.0 g/l; 1-octyl-2-pyrrolidinone ungrouped other 100.0 g/l; 1-dodecyl-2-pyrrolidinone ungrouped other 100.0 g/l; 1-methyl-2-pyrrolidinone solvent other 415.0 g/l - parasiticides

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sigma company limited - codeine phosphate hemihydrate, quantity: 15 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; povidone; ethanol; purified water; potato starch; docusate sodium - for the temporary relief of acute moderate pain in patients over the age of 12 years (see also contraindications and paediatric use).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sigma company limited - codeine phosphate hemihydrate,doxylamine succinate,paracetamol -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sigma company limited - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 15 mg - tablet, uncoated - excipient ingredients: potato starch; purified water; povidone; colloidal anhydrous silica; magnesium stearate; lactose monohydrate; docusate sodium; ethanol - for the temporary relief of acute moderate pain in patients over the age of 12 years (see also contraindications and paediatric use).

États-Unis - anglais - NLM (National Library of Medicine)

eli lilly and company - insulin glargine (unii: 2zm8cx04rz) (insulin glargine - unii:2zm8cx04rz) - insulin glargine 100 [iu] in 1 ml - basaglar® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. limitations of use basaglar is not recommended for the treatment of diabetic ketoacidosis. basaglar is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] . - in patients with hypersensitivity to insulin glargine or any of the excipients in basaglar [see warnings and precautions (5.5)] . risk summary published studies with use of insulin glargine products during pregnancy have not reported a clear association with insulin glargine products and adverse developmental outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). in animal reproduction studies, another insulin glargine product was administered to rats before, during and throughout pregnancy at doses up to 7 times the clinical dose of 10 units/day and to rabbits during organogenesis at doses approximately 2 times the clinical dose of 10 units/day. the effects of this other insulin glargine product did not generally differ from those observed with regular human insulin in rats or rabbits (see data). the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. data human data published data do not report a clear association with insulin glargine products and major birth defects, miscarriage, or adverse maternal or fetal outcomes when insulin glargine products are used during pregnancy. however, these studies cannot definitely establish the absence of any risk because of methodological limitations including small sample size and some with no comparative group. animal data subcutaneous reproduction and teratology studies have been performed with another insulin glargine product and with regular human insulin in rats and himalayan rabbits. this other insulin glargine product was given to female rats before mating, during mating, and throughout pregnancy at dose up to 0.36 mg/kg/day, which is approximately 7 times the recommended human subcutaneous starting dose of 10 units/day (0.008 mg/kg/day) based on mg/m2 . in rabbits, doses of 0.072 mg/kg/day, which is approximately 2 times the recommended human subcutaneous starting dose of 10 units/day (0.008 mg/kg/day), based on mg/m2 , were administered during organogenesis. the effects of this other insulin glargine product did not generally differ from those observed with regular human insulin in rats and rabbits. however, in rabbits, five fetuses from two litters of the high-dose group exhibited dilation of the cerebral ventricles. fertility and early embryonic development appeared normal. risk summary there are no data on the presence of insulin glargine in human milk, the effects on the breastfed infant, or the effects on milk production. endogenous insulin is present in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for basaglar and any potential adverse effects on the breastfed child from basaglar or from the underlying maternal condition. the safety and effectiveness of basaglar have been established in pediatric patients (age 6 to 15 years) with type 1 diabetes based on an adequate and well-controlled trial of another insulin glargine product, 100 units/ml, in pediatric patients (age 6 to 15 years) with type 1 diabetes and additional data in adults with type 1 diabetes [see clinical studies (14.2)] . the safety and effectiveness of basaglar in pediatric patients younger than 6 years of age with type 1 diabetes and pediatric patients with type 2 diabetes has not been established. in the pediatric clinical trial, pediatric patients (age 6 to 15 years) with type 1 diabetes had a higher incidence of severe symptomatic hypoglycemia compared to the adults in trials with type 1 diabetes [see adverse reactions (6.1)] . of the total number of subjects in clinical studies of patients with type 2 diabetes who were treated with basaglar or another insulin glargine product, 100 units/ml, each in combination with oral agents in a controlled clinical trial environment, 28.3% were 65 and over, while 4.5% were 75 and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. nevertheless, caution should be exercised when basaglar is administered to geriatric patients. in elderly patients with diabetes, the initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemic reactions. hypoglycemia may be difficult to recognize in the elderly. the effect of renal impairment on the pharmacokinetics of basaglar has not been studied. some studies with human insulin have shown increased circulating levels of insulin in patients with renal failure. frequent glucose monitoring and dose adjustment may be necessary for basaglar in patients with renal impairment [see warnings and precautions (5.3)] . the effect of hepatic impairment on the pharmacokinetics of basaglar has not been studied. however, as with all insulin products, more frequent glucose monitoring and dose adjustment may be necessary for basaglar in patients with hepatic impairment [see warnings and precautions (5.3)] . instructions for use basaglar® kwikpen® (insulin glargine) injection, for subcutaneous use 100 units/ml, 3 ml single-patient-use pen read the instructions for use before you start using basaglar and each time you get another basaglar® kwikpen® . there may be new information. this information does not take the place of talking to your healthcare provider about your medical condition or your treatment. do not share your basaglar kwikpen with other people, even if the needle has been changed. you may give other people a serious infection or get a serious infection from them. basaglar kwikpen (“pen”) is a disposable single-patient-use prefilled pen containing 300 units (3ml) of basaglar. one pen contains multiple doses of medicine. - your healthcare provider will tell you how many units to give as your dose and how to inject your prescribed dose of medicine. - you can give a dose of 1 to 80 units in a single injection. - if your prescribed dose is more than 80 units, you will need to give yourself more than 1 injection. - the plunger only moves a little with each injection, and you may not notice that it moves. when the plunger reaches the end of the cartridge, you have used all 300 units in the pen. people who are blind or have vision problems should not use the pen without help from a person trained to use the basaglar prefilled pen. how to recognize your basaglar kwikpen - pen color: light grey - dose knob: light grey with green ring on the end - labels: light grey with green color bars supplies needed to give your injection - basaglar kwikpen - kwikpen compatible needle (becton, dickinson and company pen needles recommended) - alcohol swab preparing your pen - wash your hands with soap and water. - check the pen to make sure you are taking the right type of insulin. this is especially important if you use more than 1 type of insulin. - do not use your pen past the expiration date printed on the label or for more than 28 days after you first start using the pen. - always use a new needle for each injection to help prevent infections and blocked needles. do not reuse or share your needles with other people. you may give other people a serious infection or get a serious infection from them. - pull the pen cap straight off. - do not remove the pen label. - wipe the rubber seal with an alcohol swab. - check the liquid in the pen. basaglar should look clear and colorless. do not use if it is cloudy, colored, or has particles or clumps in it. - select a new needle. - pull off the paper tab from the outer needle shield. - push the capped needle straight onto the pen and twist the needle on until it is tight. - pull off the outer needle shield. do not throw it away. - pull off the inner needle shield and throw it away. priming your pen prime before each injection. - priming means removing the air from the needle and cartridge that may collect during normal use. it is important to prime your pen before each injection so that it will work correctly. - if you do not prime before each injection, you may get too much or too little insulin. - to prime your pen, turn the dose knob to select 2 units . - hold your pen with the needle pointing up. tap the cartridge holder gently to collect air bubbles at the top. - continue holding your pen with needle pointing up. push the dose knob in until it stops, and “0” is seen in the dose window. hold the dose knob in and count to 5 slowly . you should see insulin at the tip of the needle. - if you do not see insulin, repeat the priming steps, but not more than 4 times. - if you still do not see insulin, change the needle and repeat the priming steps. small air bubbles are normal and will not affect your dose. selecting your dose - if your dose is more than 80 units, you will need to give more than 1 injection. - talk to your healthcare provider about how to give your dose. - use a new needle for each injection and repeat the priming step. - turn the dose knob to select the number of units you need to inject. the dose indicator should line up with your dose. - the pen dials 1 unit at a time. - the dose knob clicks as you turn it. - do not dial your dose by counting the clicks because you may dial the wrong dose. - the dose can be corrected by turning the dose knob in either direction until the correct dose lines up with the dose indicator. - the even numbers are printed on the dial. - the odd numbers, after the number 1, are shown as full lines. - always check the number in the dose window to make sure you have dialed the correct dose. the pen will not let you dial more than the number of units left in the pen. - if you need to inject more than the number of units left in the pen, you may either: - inject the amount left in your pen and then use a new pen to give the rest of your dose, or - get a new pen and inject the full dose. - it is normal to see a small amount of insulin left in the pen that you can not inject. giving your injection - inject your insulin as your healthcare provider has shown you. - change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. do not inject where the skin has pits, is thickened, or has lumps. do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin. - do not try to change your dose while injecting. - basaglar is injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms. - wipe the skin with an alcohol swab, and let the injection site dry before you inject your dose. - insert the needle into your skin. - push the dose knob all the way in. - continue to hold the dose knob in and slowly count to 5 before removing the needle. note: do not try to inject your insulin by turning the dose knob. you will not receive your insulin by turning the dose knob. - pull the needle out of your skin. - a drop of insulin at the needle tip is normal. it will not affect your dose. - check the number in the dose window - if you see “0” in the dose window, you have received the full amount you dialed. - if you do not see “0” in the dose window you did not receive your full dose. do not redial. insert the needle into your skin and finish your injection. - if you still do not think you received the full amount you dialed for your injection, do not start over or repeat that injection. monitor your blood glucose and call your healthcare provider for further instructions. - if you normally need to give 2 injections for your full dose, be sure to give your second injection. the plunger only moves a little with each injection, and you may not notice that it moves. if you see blood after you take the needle out of your skin, press the injection site lightly with a piece of gauze or an alcohol swab. do not rub the area. after your injection - carefully replace the outer needle shield. - unscrew the capped needle and throw it away (see disposing of pens and needles section below). - do not store the pen with the needle attached to prevent leaking, blocking the needle, and air from entering the pen. - replace the pen cap by lining up the cap clip with the dose indicator and pushing straight on. disposing of pens and needles - put your used needles in a fda-cleared sharps disposal container right away after use. do not throw away (dispose of) loose needles in your household trash. - if you do not have a fda-cleared sharps disposal container, you may use a household container that is: - made of a heavy-duty plastic, - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, - upright and stable during use, - leak-resistant, and - properly labeled to warn of hazardous waste inside the container. - when your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. there may be state or local laws about how you should throw away used needles and syringes. for more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the fda's website at: http://www.fda.gov/safesharpsdisposal - do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. do not recycle your used sharps disposal container. - the used pen may be discarded in your household trash after you have removed the needle. storing your basaglar kwikpen unused pens - store unused pens in the refrigerator at 36°f to 46°f (2°c to 8°c). - do not freeze basaglar. do not use if it has been frozen. - unused pens may be used until the expiration date printed on the label, if the pen has been kept in the refrigerator. in-use pen - store the pen you are currently using at room temperature [up to 86°f (30°c)] and away from heat and light. - throw away the pen you are using after 28 days, even if it still has insulin left in it. general information about the safe and effective use of your pen - keep your pen and needles out of the sight and reach of children. - always use a new needle for each injection. - do not share your pen or needles with other people. you may give other people a serious infection or get a serious infection from them. - do not use your pen if any part looks broken or damaged. - always carry an extra pen in case yours is lost or damaged. troubleshooting - if you can not remove the pen cap, gently twist the cap back and forth, and then pull the cap straight off. - if the dose knob is hard to push: - pushing the dose knob more slowly will make it easier to inject. - your needle may be blocked. put on a new needle and prime the pen. - you may have dust, food, or liquid inside the pen. throw the pen away and get a new pen. if you have any questions or problems with your basaglar kwikpen, contact lilly at 1-800-lillyrx (1-800- 545-5979) or call your healthcare provider for help. for more information on basaglar kwikpen and insulin, go to www.basaglar.com. scan this code to launch www.basaglar.com this instructions for use have been approved by the u.s. food and drug administration. basaglar® and basaglar® kwikpen® are trademarks of eli lilly and company. instructions for use revised: november 2022 manufactured by: eli lilly and company indianapolis, in 46285, usa us license number 1891 copyright © 2015, 2022, eli lilly and company. all rights reserved. baskp-0009-ifu-20221115 instructions for use basaglar® tempo pen™ (insulin glargine) injection, for subcutaneous use 100 units/ml, 3 ml pen, single-patient-use read the instructions for use before you start using basaglar and each time you get another basaglar tempo pen. there may be new information. this information does not take the place of talking to your healthcare provider about your medical condition or your treatment. do not share your basaglar tempo pen with other people, even if the needle has been changed. you may give other people a serious infection or get a serious infection from them. basaglar tempo pen (“pen”) is a disposable single-patient-use prefilled pen containing 300 units (3ml) of basaglar. one pen contains multiple doses of medicine. - your healthcare provider will tell you how many units to give as your dose and how to inject your prescribed dose of medicine. - you can give a dose of 1 to 80 units in a single injection. - if your prescribed dose is more than 80 units, you will need to give yourself more than 1 injection. - the plunger only moves a little with each injection, and you may not notice that it moves. when the plunger reaches the end of the cartridge, you have used all 300 units in the pen. people who are blind or have vision problems should not use the pen without help from a person trained to use the basaglar prefilled pen. this basaglar tempo pen contains a component that allows for data connectivity when used with a compatible transmitter. how to recognize your basaglar tempo pen - pen color: light grey - dose knob: light grey - labels: light grey with green color bars supplies needed to give your injection - basaglar tempo pen - tempo pen compatible needle (becton, dickinson and company pen needles recommended) - alcohol swab preparing your pen - wash your hands with soap and water. - check the pen to make sure you are taking the right type of insulin. this is especially important if you use more than 1 type of insulin. - do not use your pen past the expiration date printed on the label or for more than 28 days after you first start using the pen. - always use a new needle for each injection to help prevent infections and blocked needles. do not reuse or share your needles with other people. you may give other people a serious infection or get a serious infection from them. - pull the pen cap straight off. - do not remove the pen label. - wipe the rubber seal with an alcohol swab. - check the liquid in the pen. basaglar should look clear and colorless. do not use if it is cloudy, colored, or has particles or clumps in it. - select a new needle. - pull off the paper tab from the outer needle shield. - push the capped needle straight onto the pen and twist the needle on until it is tight. - pull off the outer needle shield. do not throw it away. - pull off the inner needle shield and throw it away. priming your pen prime before each injection. - priming means removing the air from the needle and cartridge that may collect during normal use. it is important to prime your pen before each injection so that it will work correctly. - if you do not prime before each injection, you may get too much or too little insulin. - to prime your pen, turn the dose knob to select 2 units . - hold your pen with the needle pointing up. tap the cartridge holder gently to collect air bubbles at the top. - continue holding your pen with the needle pointing up. push the dose knob in until it stops, and “0 ” is seen in the dose window. hold the dose knob in and count to 5 slowly . you should see insulin at the tip of the needle. - if you do not see insulin, repeat the priming steps 6 to 8, but not more than 4 times. - if you still do not see insulin, change the needle and repeat the priming steps 6 to 8. small air bubbles are normal and will not affect your dose. selecting your dose - you can give a dose of 1 to 80 units in a single injection. - if your dose is more than 80 units, you will need to give more than 1 injection. - talk to your healthcare provider about how to give your dose. - use a new needle for each injection and repeat the priming step. - turn the dose knob to select the number of units you need to inject. the dose indicator should line up with your dose. - the pen dials 1 unit at a time. - the dose knob clicks as you turn it. - do not dial your dose by counting the clicks because you may dial the wrong dose. - the dose can be corrected by turning the dose knob in either direction until the correct dose lines up with the dose indicator. - the even numbers are printed on the dial. - the odd numbers, after the number 1, are shown as full lines. - always check the number in the dose window to make sure you have dialed the correct dose. - the pen will not let you dial more than the number of units left in the pen. - if you need to inject more than the number of units left in the pen, you may either: - inject the amount left in your pen and then use a new pen to give the rest of your dose, or - get a new pen and inject the full dose. - it is normal to see a small amount of insulin left in the pen that you cannot inject. giving your injection - inject your insulin as your healthcare provider has shown you. - change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. do not inject where skin has pits, is thickened, or has lumps. do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin. - do not try to change your dose while injecting. - basaglar is injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms. - wipe the skin with an alcohol swab, and let the injection site dry before you inject your dose. - insert the needle into your skin. - push the dose knob all the way in. - continue to hold the dose knob in and slowly count to 5 before removing the needle. note: do not try to inject your insulin by turning the dose knob. you will not receive your insulin by turning the dose knob. - pull the needle out of your skin. - a drop of insulin at the needle tip is normal. it will not affect your dose. - check the number in the dose window - if you see “0” in the dose window, you have received the full amount you dialed. - if you do not see “0” in the dose window you did not receive your full dose. do not redial . insert the needle into your skin and finish your injection. - if you still do not think you received the full amount you dialed for your injection, do not start over or repeat that injection. monitor your blood sugar (glucose) and call your healthcare provider for further instructions. - if you normally need to give 2 injections for your full dose, be sure to give your second injection. the plunger only moves a little with each injection, and you may not notice that it moves. if you see blood after you take the needle out of your skin, press the injection site lightly with a piece of gauze or an alcohol swab. do not rub the area. after your injection - carefully replace the outer needle shield. - unscrew the capped needle and throw it away (see disposing of pens and needles section below). - do not store the pen with the needle attached to prevent leaking, blocking the needle, and air from entering the pen. - replace the pen cap by lining up the cap clip with the dose indicator and pushing straight on. disposing of pens and needles - put your used needles in a fda-cleared sharps disposal container right away after use. do not throw away (dispose of) loose needles in your household trash. - if you do not have a fda-cleared sharps disposal container, you may use a household container that is: - made of a heavy-duty plastic, - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, - upright and stable during use, - leak-resistant, and - properly labeled to warn of hazardous waste inside the container. - when your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. there may be state or local laws about how you should throw away used needles and syringes. for more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the fda's website at: http://www.fda.gov/safesharpsdisposal - do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. do not recycle your used sharps disposal container. - the used pen may be thrown away (discarded) in your household trash after you have removed the needle. storing your basaglar tempo pen unopened pens - store unopened pens in the refrigerator at 36°f to 46°f (2°c to 8°c). - do not freeze basaglar. do not use if it has been frozen. - unopened pens may be used until the expiration date printed on the label, if the pen has been kept in the refrigerator. in-use pen - store the pen you are currently using at room temperature [up to 86°f (30°c)] and away from heat and light. - throw away the pen you are using after 28 days, even if it still has insulin left in it. general information about the safe and effective use of your pen - keep your pen and needles out of the sight and reach of children. - always use a new needle for each injection. - do not share your pen or needles with other people. you may give other people a serious infection or get a serious infection from them. - do not use your pen if any part looks broken or damaged. - always carry an extra pen in case yours is lost or damaged. troubleshooting - if you cannot remove the pen cap, gently twist the cap back and forth, and then pull the cap straight off. - if the dose knob is hard to push: - pushing the dose knob more slowly will make it easier to inject. - your needle may be blocked. put on a new needle and prime the pen. - you may have dust, food, or liquid inside the pen. throw the pen away and get a new pen. if you have any questions or problems with your basaglar tempo pen, contact lilly at 1-800-lillyrx (1-800-545-5979) or call your healthcare provider for help. for more information on basaglar tempo pen and insulin, go to www.basaglar.com. scan this code to launch www.basaglar.com this instructions for use have been approved by the u.s. food and drug administration. basaglar® is a registered trademark and tempo pentm is a trademark of eli lilly and company. instructions for use revised: november 2022 manufactured by: eli lilly and company indianapolis, in 46285, usa us license number 1891 copyright © 2021, 2022, eli lilly and company. all rights reserved. bastp-0004-ifu-20221115

États-Unis - anglais - NLM (National Library of Medicine)

becton dickinson and company - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 9 mg in 1 ml - intravenous solutions containing sodium chloride are indicated for parenteral replenishment of fluid and sodium chloride as required by the clinical condition of the patient. none known. check flexible container solution composition, lot number, and expiry date. do not remove solution container from its overwrap until immediately before use. use sterile equipment and aseptic technique. to open - turn solution container over so that the text is face down. using the pre-cut corner tabs, peel open the overwrap and remove solution container. - check the solution container for leaks by squeezing firmly. if leaks are found, or if the seal is not intact, discard the solution. - do not use if the solution is cloudy or a precipitate is present. to add medication - identify white additive port with arrow pointing toward container. - immediately before injecting additives, break off white additive port cap with the arrow pointing toward container. - hold base of white additive port horizontally. - insert needle horizontally through the center of white additive port's septum and inject additives. - mix container contents thoroughly. preparation for administration - immediately before inserting the infusion set, break off blue infusion port cap with the arrow pointing away from container. - use a non-vented infusion set or close the air-inlet on a vented set. - close the roller clamp of the infusion set. - hold the base of blue infusion port. - insert spike through blue infusion port by rotating wrist slightly until the spike is inserted. note: see full directions accompanying administration set. warning: do not use flexible container in series connections.

États-Unis - anglais - NLM (National Library of Medicine)

h.j. harkins company, inc. - diclofenac epolamine (unii: x5f8ekl9zg) (diclofenac - unii:144o8ql0l1) - diclofenac epolamine 180 mg - - flector patch is contraindicated in patients with a known hypersensitivity to diclofenac. - flector patch is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.13)]. - flector patch is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. - flector patch is contraindicated for use on non-intact or damaged skin resulting from any etiology, including exudative dermatitis, eczema, infection lesions, burns or wounds. teratogenic effects pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation. starting at 30 weeks gestation, avoid use of flector patch, and other nsaids, in pregnant women as premature closure of the ductus arteriosus in the fetus may occur, flector pat

États-Unis - anglais - NLM (National Library of Medicine)

h.j. harkins company, inc. - zaleplon (unii: s62u433rmh) (zaleplon - unii:s62u433rmh) - zaleplon 10 mg - zaleplon is indicated for the short-term treatment of insomnia. zaleplon has been shown to decrease the time to sleep onset for up to 30 days in controlled clinical studies (see clinical trials under clinical pharmacology). it has not been shown to increase total sleep time or decrease the number of awakenings. the clinical trials performed in support of efficacy ranged from a single night to 5 weeks in duration. the final formal assessments of sleep latency were performed at the end of treatment. hypersensitivity to zaleplon or any excipients in the formulation (see also precautions). controlled substance class zaleplon is classified as a schedule iv controlled substance by federal regulation. abuse, dependence, and tolerance abuse and addiction are separate and distinct from physical dependence and tolerance. abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. physical dependence is a state of adaption that is manifested by a specif